6YTM image
Deposition Date 2020-04-24
Release Date 2020-05-27
Last Version Date 2024-01-24
Entry Detail
PDB ID:
6YTM
Keywords:
Title:
Human Brd2(BD2) L383V mutant in complex with ET-JQ1-OMe
Biological Source:
Source Organism:
Homo sapiens (Taxon ID: 9606)
Host Organism:
Method Details:
Experimental Method:
Resolution:
1.56 Å
R-Value Free:
0.20
R-Value Work:
0.17
R-Value Observed:
0.17
Space Group:
P 21 21 21
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:Bromodomain-containing protein 2
Gene (Uniprot):BRD2
Mutations:L383V
Chain IDs:A, B
Chain Length:114
Number of Molecules:2
Biological Source:Homo sapiens
Primary Citation
Stereoselective synthesis of allele-specific BET inhibitors.
Org.Biomol.Chem. 18 7533 7539 (2020)
PMID: 32756710 DOI: 10.1039/d0ob01165g

Abstact

Developing stereoselective synthetic routes that are efficient and cost-effective allows easy access to biologically active molecules. Our previous syntheses of allele-selective bumped inhibitors of the Bromo and Extra-Terminal (BET) domain proteins, Brd2, Brd3, Brd4 and BrdT, required a wasteful, late-stage alkylation step and expensive chiral separation. To circumvent these limitations, we developed a route based on stereocontrolled alkylation of an N-Pf protected aspartic acid derivative that was used in a divergent, racemisation-free protocol to yield structurally diverse and enantiopure triazolodiazepines. With this approach, we synthesized bumped thienodiazepine-based BET inhibitor, ET-JQ1-OMe, in five steps and 99% ee without the need for chiral chromatography. Exquisite selectivity of ET-JQ1-OMe for Leu-Ala and Leu-Val mutants over wild-type bromodomain was established by isothermal titration calorimetry and X-ray crystallography. Our new approach provides unambiguous chemical evidence for the absolute stereochemistry of the active, allele-specific BET inhibitors and a viable route that will open wider access to this compound class.

Legend

Protein

Chemical

Disease

Primary Citation of related structures